Skip to main content

Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.

Publication ,  Journal Article
Plonowski, A; Schally, AV; Nagy, A; Sun, B; Halmos, G
Published in: Int J Oncol
February 2002

We evaluated the effectiveness of targeted cytotoxic analog of somatostatin (SST) AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked covalently to SST octapeptide carrier RC-121 in DU-145 human androgen-independent prostate cancers xenografted into nude mice. We also investigated the expression of mRNAs for SST receptor subtypes 2A and 5 (sst2A and sst5) in DU-145 tumors. After 8 weeks of treatment, AN-238 practically arrested the proliferation of DU-145 cancers. The tumor volume in nude mice that received 4 injections of AN-238 at the dose of 150 nmol/kg was 63.4+/-6.7 mm3, nearly 4 times smaller than that in controls which measured 249.1+/-36.3 mm3 (p<0.001). Treatment with AN-238 lowered tumor weight by 68% (p<0.01) compared with the control group and extended the tumor volume doubling time to 184.1+/-69.4 days, versus 32.1+/-6.6 days in controls (p<0.05). No toxicity-related deaths occurred during treatment with AN-238. Cytotoxic radical AN-201 administered alone or in an unconjugated mixture with carrier RC-121 inhibited the growth of DU-145 tumors only after the third and fourth injection and was toxic. The expression of mRNA for sst2A and sst5 was detected in all specimens of control DU-145 tumors and in tumors treated with AN-238. The present study demonstrates the high efficacy of SST-receptor-targeted chemotherapy in a model of human androgen-independent prostatic carcinoma.

Duke Scholars

Published In

Int J Oncol

ISSN

1019-6439

Publication Date

February 2002

Volume

20

Issue

2

Start / End Page

397 / 402

Location

Greece

Related Subject Headings

  • Tumor Cells, Cultured
  • Treatment Outcome
  • Reverse Transcriptase Polymerase Chain Reaction
  • RNA, Neoplasm
  • RNA, Messenger
  • Pyrroles
  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Octreotide
  • Neoplasms, Experimental
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Plonowski, A., Schally, A. V., Nagy, A., Sun, B., & Halmos, G. (2002). Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol, 20(2), 397–402.
Plonowski, Artur, Andrew V. Schally, Attila Nagy, Baodong Sun, and Gabor Halmos. “Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.Int J Oncol 20, no. 2 (February 2002): 397–402.
Plonowski A, Schally AV, Nagy A, Sun B, Halmos G. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol. 2002 Feb;20(2):397–402.
Plonowski, Artur, et al. “Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.Int J Oncol, vol. 20, no. 2, Feb. 2002, pp. 397–402.
Plonowski A, Schally AV, Nagy A, Sun B, Halmos G. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol. 2002 Feb;20(2):397–402.

Published In

Int J Oncol

ISSN

1019-6439

Publication Date

February 2002

Volume

20

Issue

2

Start / End Page

397 / 402

Location

Greece

Related Subject Headings

  • Tumor Cells, Cultured
  • Treatment Outcome
  • Reverse Transcriptase Polymerase Chain Reaction
  • RNA, Neoplasm
  • RNA, Messenger
  • Pyrroles
  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Octreotide
  • Neoplasms, Experimental